On Feb. 13, 2002, U.S. Army Staff Sergeant Terrence Dillon underwent a surgical procedure and received a new cholesterol treatment device known as the “NewLife Stent.” Not only was the stent designed to cleanse blood of cholesterol, its specialized chemical compound would actually dissolve cholesterol plaque blocking the arteries. Unfortunately for Sergeant Dillon, the stent worked far too well.
On March 2, Dillon died after suffering a stroke. An autopsy revealed that the stent was more powerful than its designers had thought, loosening immense amounts of plaque that clogged Dillon’s circulatory system. The tragedy resulted in a criminal indictment against the stent’s manufacturer, NewLife MedTech.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
